Tanuj Malhotra
Independent Researcher
Delhi, India
Abstract
Guselkumab, an IL-23 inhibitor, has demonstrated clinical efficacy in managing moderate-to-severe plaque psoriasis. However, limited data exists regarding patient-reported outcomes (PROs) using real-time digital tools. This study investigates the usability and effectiveness of a mobile application designed to capture PROs among psoriasis patients undergoing Guselkumab therapy. We conducted a prospective observational study using a digital platform to collect longitudinal data on symptom burden, treatment satisfaction, and quality of life indicators over 24 weeks. The study enrolled 132 patients from multiple dermatology centers. Our findings indicated statistically significant improvements in dermatology life quality index (DLQI) scores and high levels of patient engagement with the app. Moreover, real-time tracking facilitated better patient-physician communication and informed clinical adjustments. The app demonstrated feasibility in gathering meaningful, patient-centered insights, underscoring the value of digital health technologies in chronic dermatologic care.
Keywords
Guselkumab, patient-reported outcomes, psoriasis, digital health, mobile application, IL-23 inhibitors, quality of life, dermatology, ePRO, real-world evidence
References
- Blauvelt A, Papp K A, Griffiths C E M, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for plaque psoriasis (VOYAGE 1): a randomised, double-blind, controlled trial. J Am Acad Dermatol. 2017;76(3):405-417. doi:10.1016/j.jaad.2016.11.041. ncbi.nlm.nih.gov
- Reich K, Armstrong A W, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for moderate-to-severe psoriasis: results from the Phase III VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418-431. doi:10.1016/j.jaad.2016.11.042. ncbi.nlm.nih.gov
- Langley R G, Tsai T F, Flavin S, et al. Guselkumab for patients with psoriasis who have an inadequate response to ustekinumab: results of the randomised, double-blind Phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114-123. doi:10.1111/bjd.15750. ncbi.nlm.nih.gov
- Gordon K B, Duffin K C, Bissonnette R, et al. A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136-144. doi:10.1056/NEJMoa1501646. ncbi.nlm.nih.gov
- Svendsen M T, Andersen F, Andersen K H, Andersen K E. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomised controlled trial. BMC Dermatol. 2018;18(1):2. doi:10.1186/s12895-018-0071-3. ncbi.nlm.nih.gov
- Chambers C J, Parsi K K, Schupp C, Armstrong A W. Patient-centred online management of psoriasis: a randomised controlled equivalency trial. J Am Acad Dermatol. 2012;66(6):948-953. doi:10.1016/j.jaad.2011.05.047. ncbi.nlm.nih.gov
- Ariens L F M, Schussler-Raymakers F M L, Frima C, et al. Barriers and facilitators to eHealth use in daily practice: perspectives of patients and professionals in dermatology. J Med Internet Res. 2017;19(9):e300. doi:10.2196/jmir.7512. ncbi.nlm.nih.gov
- Schreier G, Hayn D, Kastner P, et al. A mobile-phone-based teledermatology system to support self-management of patients suffering from psoriasis. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:5338-5341. doi:10.1109/IEMBS.2008.4650420. net
- Finlay A Y, Khan G K. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x. ncbi.nlm.nih.gov
- Bushnell D M, Martin M L, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24(5):356-360. doi:10.3109/09546634.2012.742950.